Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.

about

Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?A safety evaluation of raltegravir for the treatment of HIV.

P2860

Q38874266-75EA96FB-C96D-451D-86B7-35A5E4A09279 Q47332682-DA25057E-DB2E-42E1-A463-263205873FC5 Q47377203-DA784B8F-AF7F-4CF9-8281-CEF5D19202EF

P2860

Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.

Item

http://www.wikidata.org/entity/Q41143073

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pharmacokinetics of Raltegravi ...... -Based Antitubercular Therapy.

@en

type

Item

label

Pharmacokinetics of Raltegravi ...... -Based Antitubercular Therapy.

@en

prefLabel

Pharmacokinetics of Raltegravi ...... -Based Antitubercular Therapy.

@en

P1476

Pharmacokinetics of Raltegravi ...... -Based Antitubercular Therapy.

@en

P2093

Alex Assuied

http://www.w3.org/2001/XMLSchema#string

Anne-Marie Taburet

http://www.w3.org/2001/XMLSchema#string

Carine Grondin

http://www.w3.org/2001/XMLSchema#string

Catherine Fagard

http://www.w3.org/2001/XMLSchema#string

Hélène Sauvageon

http://www.w3.org/2001/XMLSchema#string

Jean-Michel Molina

http://www.w3.org/2001/XMLSchema#string

José Henrique Pilotto

http://www.w3.org/2001/XMLSchema#string

Nathalie De Castro

http://www.w3.org/2001/XMLSchema#string

Valdilea Veloso

http://www.w3.org/2001/XMLSchema#string

P2860

PharmGKB summary: very important pharmacogene information for UGT1A1

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.

Integration of antiretroviral therapy with tuberculosis treatment.

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.

Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients

Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing.

Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.

Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.

Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.

P304

1328-1335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIV477

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Beatriz Grinsztejn

P577

2015-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26105170

http://www.w3.org/2001/XMLSchema#string

Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.

about

P2860

P2860

Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698